Clinical Trial Update: Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing drotaverine hydrochloride to hyoscine-N-butylbromide for duodenal antimotility during ERCP has been completed with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bile Duct Diseases
• Pancreatic Diseases

Drugs mentioned

• Drotaverine hydrochloride (drotaverine hydrochloride)
• Hyoscine-n-butylbromide (hyoscine butylbromide)

Snippet

Sponsor: Changhai Hospital | Conditions: ERCP, Pancreatic Diseases | Phase 3 | Status: COMPLETED | Results posted: 2009-12-23